$CORT News

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript

Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est

Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's Syndrome

Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)

CORT Stock Rises 42% in a Month: Here's What You Should Know

Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes